Immunic, Inc. (IMUX): Price and Financial Metrics

Immunic, Inc. (IMUX): $1.24

0.01 (+0.81%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add IMUX to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#193 of 359

in industry

IMUX Price/Volume Stats

Current price $1.24 52-week high $3.11
Prev. close $1.23 52-week low $0.95
Day low $1.23 Volume 204,400
Day high $1.31 Avg. volume 858,521
50-day MA $1.33 Dividend yield N/A
200-day MA $1.45 Market Cap 111.51M

IMUX Stock Price Chart Interactive Chart >


Immunic, Inc. (IMUX) Company Bio


Immunic Inc. (formerly Vital Therapies) is a biotherapeutic company developing a cell-based therapy targeting the treatment of liver failure. The company was founded in 2003 and is based in San Diego, California.


IMUX Latest News Stream


Event/Time News Detail
Loading, please wait...

IMUX Latest Social Stream


Loading social stream, please wait...

View Full IMUX Social Stream

Latest IMUX News From Around the Web

Below are the latest news stories about IMMUNIC INC that investors may wish to consider to help them evaluate IMUX as an investment opportunity.

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/992,162, entitled, "Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases."

Yahoo | November 21, 2023

Immunic focusing on business development during Q4

Immunic Inc President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive London after the Munich-based biotech company released a third-quarter update.

Yahoo | November 14, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced financial results for the third quarter ended September 30, 2023, and provided a corporate update.

Yahoo | November 14, 2023

Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that the company will release its financial results for the third quarter ended September 30, 2023, including a corporate update, on Tuesday, November 14, 2023, before the opening of the U.S. financial markets. A webcast will follow at 8:00 am ET.

Yahoo | November 7, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 17/391,442, entitled, "Treatment of Multiple Sclerosis Comprising DHODH Inhibitors," covering a daily dose of about 10 mg to 45 mg of vidofludimus calcium (IMU-838) and other

Yahoo | November 2, 2023

Read More 'IMUX' Stories Here

IMUX Price Returns

1-mo -4.62%
3-mo 8.77%
6-mo 16.98%
1-year -20.51%
3-year -91.51%
5-year -91.66%
YTD -17.33%
2023 7.14%
2022 -85.37%
2021 -37.41%
2020 57.63%
2019 27.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!